✦ LIBER ✦

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

✍ Scribed by Pina M. Cardarelli; Chetana Rao-Naik; Sharline Chen; Haichun Huang; Amie Pham; Maria-Cristina Moldovan-Loomis; Chin Pan; Ben Preston; David Passmore; Jie Liu; Michelle R. Kuhne; Alison Witte; Diann Blanset; David J. King

Book ID: 105967659
Publisher: Springer-Verlag
Year: 2009
Tongue: English
Weight: 385 KB
Volume: 59
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-009-0746-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A novel anti-CD19 monoclonal antibody (G

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

✍ Breton, Caroline S; Nahimana, Aimable; Aubry, Dominique; Macoin, Julie; Moretti, 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 843 KB

Characterization of a humanized anti-CD2

Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma

✍ Lan Wu; Chong Wang; Dapeng Zhang; Xunming Zhang; Weizhu Qian; Lei Zhao; Hao Wang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 781 KB

T-cell activation and B-cell depletion i

T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

✍ Bernd Schlereth; Cornelia Quadt; Torsten Dreier; Peter Kufer; Grit Lorenczewski; 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 412 KB

A novel Fc-engineered monoclonal antibod

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

✍ Heider, K.-H.; Kiefer, K.; Zenz, T.; Volden, M.; Stilgenbauer, S.; Ostermann, E. 📂 Article 📅 2011 🏛 American Society of Hematology 🌐 English ⚖ 604 KB

Inhibition of B cell receptor-mediated a

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies

✍ Seung Y. Chu; Igor Vostiar; Sher Karki; Gregory L. Moore; Greg A. Lazar; Erik Po 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 558 KB

Chimeric, divalent and tetravalent anti-

Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines

✍ Xiao-Yun Liu; Laurentiu M. Pop; Lydia Tsai; Iliodora V. Pop; Ellen S. Vitetta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 295 KB

## Abstract CD19 is an attractive therapeutic target for treating human B‐cell tumors. In our study, chimeric (c) divalent (cHD37) and tetravalent (cHD37‐DcVV) anti‐CD19 monoclonal antibodies (MAbs) were constructed, expressed and evaluated for their binding to human 19‐positive (CD19^+^) tumor cel